ID: MRFR/HC/6967-HCR | 90 Pages | Author: Kinjoll Dey | March 2024
Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porterβs Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE
6.1. Overview
6.2. Monoclonal Antibodies
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.3. Recombinant Growth Factors
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.3.1. Erythropoietin
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.3.2. Granulocyte Colony Stimulating Factor
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.4. Purified Proteins
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.4.1. Leukemia Inhibitory Factor (LIF)
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.4.2. P53 Protein
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.4.3. P38 Protein
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.4.4. Others
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.5. Recombinant Proteins
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.5.1. Serum Albumin
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.5.2. Amyloid Protein
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.5.3. Defensin
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.5.4. Transferrin
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.5.5. Others
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.6. Recombinant Hormones
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7. Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.1. Recombinant Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.1.1. Cancer Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.1.2. Malaria Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.1.3. Ebola Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.1.4. Hepatitis B Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.1.5. Tetanus Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.1.6. Diptheria Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.1.7. Cholera Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.1.8. Others
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.2. Conventional Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.2.1. Polio Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.2.2. Pox Vaccines
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.2.3. Others
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.7.3. Others
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.8. Synthetic Immunomodulators
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.8.1. Cytokines, Interferones, Interleukins
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.8.2. Tumor Necrosis Factor (TNF)
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.8.3. Others
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
6.9. Others
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
7. GLOBAL BIOPHARMACEUTICALS MARKET, BY APPLICATION
7.1. Overview
7.2. Oncology
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
7.3. Inflammatory and Infectious Diseases
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
7.4. Autoimmune Disorders
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
7.5. Metabolic Disorders
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
7.6. Hormonal Disorders
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
7.7. Disease Prevention
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
7.8. Cardiovascular Diseases
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
7.9. Neurological Diseases
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
7.10. Others
Market Estimates & Forecast, by Region, 2019β2027
Market Estimates & Forecast, by Country, 2019β2027
8. GLOBAL BIOPHARMACEUTICALS MARKET, BY REGION
8.1. Overview
8.2. Americas
8.2.1. North America
8.2.1.1. US
8.2.1.2. Canada
8.2.2. Latin America
8.3. Europe
8.3.1. Western Europe
8.3.1.1. Germany
8.3.1.2. France
8.3.1.3. Italy
8.3.1.4. Spain
8.3.1.5. UK
8.3.1.6. Rest of Western Europe
8.3.2. Eastern Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle East & Africa
8.5.1. Middle East
8.5.2. Africa
9. COMPANY LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Biopharmaceuticals Market
9.5. Competitive Benchmarking
9.6. Leading Players in terms of Number of Developments in the Global Biopharmaceuticals Market
9.7. Key developments and Growth Strategies
9.7.1. New Product Launch/Service Deployment
9.7.2. Merger & acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix & Market Ratio
9.8.1. Sales & Operating Income 2019
9.8.2. Major Players R&D Expenditure 2019
9.9. Major Players Capital Market Ratio
10. COMPANY PROFILES
10.1. Pfizer, Inc.
10.1.1. Company Overview
10.1.2. Product Overview
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Amgen Inc.
10.2.1. Company Overview
10.2.2. Product Overview
10.2.3. Financial Overview
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. Eli Lilly and Company
10.3.1. Company Overview
10.3.2. Product Overview
10.3.3. Financial Overview
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. F. Hoffmann-La Roche Ltd
10.4.1. Company Overview
10.4.2. Product Overview
10.4.3. Financial Overview
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Johnson & Johnson
10.5.1. Company Overview
10.5.2. Product Overview
10.5.3. Financial Overview
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Gilead Sciences, Inc.
10.6.1. Company Overview
10.6.2. Product Overview
10.6.3. Financial Overview
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. AstraZeneca
10.7.1. Company Overview
10.7.2. Product Overview
10.7.3. Financial Overview
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Abbvie Inc.
10.8.1. Company Overview
10.8.2. Product Overview
10.8.3. Financial Overview
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Sanofi
10.9.1. Company Overview
10.9.2. Product Overview
10.9.3. Financial Overview
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Bristol-Myers Squibb Company
10.10.1. Company Overview
10.10.2. Product Overview
10.10.3. Financial Overview
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. Sandoz International GmbH
10.11.1. Company Overview
10.11.2. Product Overview
10.11.3. Financial Overview
10.11.4. Key Developments
10.11.5. SWOT Analysis
10.11.6. Key Strategies
10.12. Novo Nordisk A/S
10.12.1. Company Overview
10.12.2. Product Overview
10.12.3. Financial Overview
10.12.4. Key Developments
10.12.5. SWOT Analysis
10.12.6. Key Strategies
10.13. GlaxoSmithKline PLC
10.13.1. Company Overview
10.13.2. Product Overview
10.13.3. Financial Overview
10.13.4. Key Developments
10.13.5. SWOT Analysis
10.13.6. Key Strategies
10.14. Merck KGaA
10.14.1. Company Overview
10.14.2. Product Overview
10.14.3. Financial Overview
10.14.4. Key Developments
10.14.5. SWOT Analysis
10.14.6. Key Strategies
10.15. Biocon
10.15.1. Company Overview
10.15.2. Product Overview
10.15.3. Financial Overview
10.15.4. Key Developments
10.15.5. SWOT Analysis
10.15.6. Key Strategies
10.16. Others
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL BIOPHARMACEUTICALS MARKET SYNOPSIS, 2019β2027
TABLE 2 GLOBAL BIOPHARMACEUTICALS MARKET ESTIMATES & FORECAST, 2019β2027 (USD MILLION)
TABLE 3 GLOBAL BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019β2027 (USD MILLION)
TABLE 4 GLOBAL BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019β2027 (USD MILLION)
TABLE 5 GLOBAL BIOPHARMACEUTICALS MARKET, BY REGION, 2019β2027 (USD MILLION)
TABLE 6 NORTH AMERICA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019β2027 (USD MILLION)
TABLE 7 NORTH AMERICA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019β2027 (USD MILLION)
TABLE 8 US: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019β2027 (USD MILLION)
TABLE 9 US: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019β2027 (USD MILLION)
TABLE 10 CANADA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019β2027 (USD MILLION)
TABLE 11 CANADA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019β2027 (USD MILLION)
TABLE 12 LATIN AMERICA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019β2027 (USD MILLION)
TABLE 13 LATIN AMERICA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019β2027 (USD MILLION)
TABLE 14 EUROPE: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019β2027 (USD MILLION)
TABLE 15 EUROPE: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019β2027 (USD MILLION)
TABLE 16 WESTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019β2027 (USD MILLION)
TABLE 17 WESTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019β2027 (USD MILLION)
TABLE 18 EASTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019β2027 (USD MILLION)
TABLE 19 EASTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019β2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019β2027 (USD MILLION)
TABLE 21 ASIA-PACIFIC: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019β2027 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019β2027 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019β2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BIOPHARMACEUTICALS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BIOPHARMACEUTICALS MARKET
FIGURE 4 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY PRODUCT TYPE, 2019 (%)
FIGURE 5 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY APPLICATION, 2019 (%)
FIGURE 6 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY REGION, 2019 (%)
FIGURE 7 AMERICAS: BIOPHARMACEUTICALS MARKET SHARE BY REGION, 2019 (%)
FIGURE 7 NORTH AMERICA: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 8 EUROPE: BIOPHARMACEUTICALS MARKET SHARE, BY REGION, 2019 (%)
FIGURE 9 WESTERN EUROPE: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 10 ASIA-PACIFIC: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 11 MIDDLE EAST & AFRICA: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 12 GLOBAL BIOPHARMACEUTICALS MARKET: COMPANY SHARE ANALYSIS, 2019 (%)
FIGURE 13 PFIZER, INC..: KEY FINANCIALS
FIGURE 14 PFIZER, INC.: SEGMENTAL REVENUE
FIGURE 15 PFIZER, INC.: REGIONAL REVENUE
FIGURE 16 AMGEN INC.: KEY FINANCIALS
FIGURE 17 AMGEN INC.: SEGMENTAL REVENUE
FIGURE 18 AMGEN INC.: REGIONAL REVENUE
FIGURE 19 ELI LILLY AND COMPANY: KEY FINANCIALS
FIGURE 20 ELI LILLY AND COMPANY: SEGMENTAL REVENUE
FIGURE 21 ELI LILLY AND COMPANY: REGIONAL REVENUE
FIGURE 22 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS
FIGURE 23 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE
FIGURE 24 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE
FIGURE 25 JOHNSON & JOHNSON: KEY FINANCIALS
FIGURE 26 JOHNSON & JOHNSON: SEGMENTAL REVENUE
FIGURE 27 JOHNSON & JOHNSON: REGIONAL REVENUE
FIGURE 28 GILEAD SCIENCES, INC.: KEY FINANCIALS
FIGURE 29 GILEAD SCIENCES, INC.: SEGMENTAL REVENUE
FIGURE 30 GILEAD SCIENCES, INC.: REGIONAL REVENUE
FIGURE 31 ASTRAZENECA: KEY FINANCIALS
FIGURE 32 ASTRAZENECA: SEGMENTAL REVENUE
FIGURE 33 ASTRAZENECA: REGIONAL REVENUE
FIGURE 34 ABBVIE INC.: KEY FINANCIALS
FIGURE 35 ABBVIE INC.: SEGMENTAL REVENUE
FIGURE 36 ABBVIE INC.: REGIONAL REVENUE
FIGURE 37 SANOFI: KEY FINANCIALS
FIGURE 38 SANOFI: SEGMENTAL REVENUE
FIGURE 39 SANOFI: REGIONAL REVENUE
FIGURE 40 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS
FIGURE 41 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE
FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE
FIGURE 43 SANDOZ INTERNATIONAL GMBH: KEY FINANCIALS
FIGURE 44 SANDOZ INTERNATIONAL GMBH: SEGMENTAL REVENUE
FIGURE 45 SANDOZ INTERNATIONAL GMBH: REGIONAL REVENUE
FIGURE 46 NOVO NORDISK A/S: KEY FINANCIALS
FIGURE 47 NOVO NORDISK A/S: SEGMENTAL REVENUE
FIGURE 48 NOVO NORDISK A/S: REGIONAL REVENUE
FIGURE 49 GLAXOSMITHKLINE PLC: KEY FINANCIALS
FIGURE 50 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE
FIGURE 51 GLAXOSMITHKLINE PLC: REGIONAL REVENUE
FIGURE 52 MERCK KGAA: KEY FINANCIALS
FIGURE 53 MERCK KGAA: SEGMENTAL REVENUE
FIGURE 54 MERCK KGAA: REGIONAL REVENUE
FIGURE 55 BIOCON: KEY FINANCIALS
FIGURE 56 BIOCON: SEGMENTAL REVENUE
FIGURE 57 BIOCON: REGIONAL REVENUE